164 related articles for article (PubMed ID: 12871949)
1. Cellular heparan sulfate participates in the metabolism of prions.
Ben-Zaken O; Tzaban S; Tal Y; Horonchik L; Esko JD; Vlodavsky I; Taraboulos A
J Biol Chem; 2003 Oct; 278(41):40041-9. PubMed ID: 12871949
[TBL] [Abstract][Full Text] [Related]
2. PrPc does not mediate internalization of PrPSc but is required at an early stage for de novo prion infection of Rov cells.
Paquet S; Daude N; Courageot MP; Chapuis J; Laude H; Vilette D
J Virol; 2007 Oct; 81(19):10786-91. PubMed ID: 17626095
[TBL] [Abstract][Full Text] [Related]
3. Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation.
Burke CM; Walsh DJ; Mark KMK; Deleault NR; Nishina KA; Agrimi U; Di Bari MA; Supattapone S
PLoS Pathog; 2020 Apr; 16(4):e1008495. PubMed ID: 32294141
[TBL] [Abstract][Full Text] [Related]
4. Prion protein conversion in vitro.
Supattapone S
J Mol Med (Berl); 2004 Jun; 82(6):348-56. PubMed ID: 15014886
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation-related gene expression in prion diseases: PrPSc accumulation in scrapie infected GT1 cells depends on beta-1,4-linked GalNAc-4-SO4 hyposulfation.
Barret A; Forestier L; Deslys JP; Julien R; Gallet PF
J Biol Chem; 2005 Mar; 280(11):10516-23. PubMed ID: 15632154
[TBL] [Abstract][Full Text] [Related]
6. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.
Wolf H; Graßmann A; Bester R; Hossinger A; Möhl C; Paulsen L; Groschup MH; Schätzl H; Vorberg I
J Virol; 2015 Oct; 89(19):9853-64. PubMed ID: 26202247
[TBL] [Abstract][Full Text] [Related]
8. Heparan sulfate is a cellular receptor for purified infectious prions.
Horonchik L; Tzaban S; Ben-Zaken O; Yedidia Y; Rouvinski A; Papy-Garcia D; Barritault D; Vlodavsky I; Taraboulos A
J Biol Chem; 2005 Apr; 280(17):17062-7. PubMed ID: 15668247
[TBL] [Abstract][Full Text] [Related]
9. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
Bate C; Tayebi M; Williams A
BMC Biol; 2008 Feb; 6():8. PubMed ID: 18269734
[TBL] [Abstract][Full Text] [Related]
10. Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells.
Bate C; Tayebi M; Diomede L; Salmona M; Williams A
BMC Biol; 2008 Sep; 6():39. PubMed ID: 18789130
[TBL] [Abstract][Full Text] [Related]
11. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate.
Gabizon R; Meiner Z; Halimi M; Ben-Sasson SA
J Cell Physiol; 1993 Nov; 157(2):319-25. PubMed ID: 7901226
[TBL] [Abstract][Full Text] [Related]
12. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
Kellershohn N; Laurent M
Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
[TBL] [Abstract][Full Text] [Related]
13. A receptor for infectious and cellular prion protein.
Martins VR
Braz J Med Biol Res; 1999 Jul; 32(7):853-9. PubMed ID: 10454744
[TBL] [Abstract][Full Text] [Related]
14. Non-genetic propagation of strain-specific properties of scrapie prion protein.
Bessen RA; Kocisko DA; Raymond GJ; Nandan S; Lansbury PT; Caughey B
Nature; 1995 Jun; 375(6533):698-700. PubMed ID: 7791905
[TBL] [Abstract][Full Text] [Related]
15. Protease resistance of infectious prions is suppressed by removal of a single atom in the cellular prion protein.
Leske H; Hornemann S; Herrmann US; Zhu C; Dametto P; Li B; Laferriere F; Polymenidou M; Pelczar P; Reimann RR; Schwarz P; Rushing EJ; Wüthrich K; Aguzzi A
PLoS One; 2017; 12(2):e0170503. PubMed ID: 28207746
[TBL] [Abstract][Full Text] [Related]
16. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation.
Alleaume-Butaux A; Nicot S; Pietri M; Baudry A; Dakowski C; Tixador P; Ardila-Osorio H; Haeberlé AM; Bailly Y; Peyrin JM; Launay JM; Kellermann O; Schneider B
PLoS Pathog; 2015 Aug; 11(8):e1005073. PubMed ID: 26241960
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PrPSc formation by synthetic O-sulfated glycopyranosides and their polymers.
Yamaguchi S; Nishida Y; Sasaki K; Kambara M; Kim CL; Ishiguro N; Nagatsuka T; Uzawa H; Horiuchi M
Biochem Biophys Res Commun; 2006 Oct; 349(2):485-91. PubMed ID: 16949037
[TBL] [Abstract][Full Text] [Related]
18. Altered distribution, aggregation, and protease resistance of cellular prion protein following intracranial inoculation.
Ward A; Hollister JR; Choi YP; Race B; Williams K; Shoup DW; Moore RA; Priola SA
PLoS One; 2019; 14(7):e0219457. PubMed ID: 31291644
[TBL] [Abstract][Full Text] [Related]
19. No influence of amyloid-beta-degrading neprilysin activity on prion pathogenesis.
Glatzel M; Mohajeri MH; Poirier R; Nitsch RM; Schwarz P; Lu B; Aguzzi A
J Gen Virol; 2005 Jun; 86(Pt 6):1861-1867. PubMed ID: 15914866
[TBL] [Abstract][Full Text] [Related]
20. Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.
Karpuj MV; Giles K; Gelibter-Niv S; Scott MR; Lingappa VR; Szoka FC; Peretz D; Denetclaw W; Prusiner SB
Mol Med; 2007; 13(3-4):190-8. PubMed ID: 17592554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
